

May 23rd, 2025

Dept. of Corporate Services
BSE Ltd.
P J Towers,
Dalal Street,
Mumbai – 400 001.

Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza,
Bandra Kurla Complex
Bandra (East), Mumbai 400051.

BSE Scrip Code: 524735

NSE Symbol: HIKAL

Subject: Hikal's Jigani Unit- US FDA Inspection - Updates.

Ref : Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Dear Sir / Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to our intimation dated 8th February 2025 regarding the United States Food and Drug Administration (US FDA) inspection of one of our manufacturing facilities at Jigani, Bengaluru, Karnataka from February 3rd to February 7th, 2025. We hereby notify that the Company has received communication from the US FDA that the inspection outcome has been classified as "Official Action Indicated" (OAI).

The Company at this point of time believes that this inspection classification will not have any impact on business continuity or supplies of existing products from this facility.

The Company remains committed to work closely with the US FDA and maintaining the highest quality and compliant manufacturing standards at all of its facilities and enhance its compliance on an ongoing basis.

We request you to take the above on record.

Thanking you,

Yours Sincerely,
for HIKAL LIMITED,

Rajasekhar Reddy
Company Secretary and Compliance Officer

Hikal Ltd.

Admin. Office: Great Eastern Chambers, 6th Floor, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India. Tel. + 91-22-6277 0299, + 91-22-6866 0300

Regd. Office: 717, Maker Chambers - 5, Nariman Point, Mumbai - 400 021, India. Tel. +91-22 6277 0477. Fax: + 91-22 6277 0500

www.hikal.com info@hikal.com CIN: L24200MH1988PTC048028